NPSP Key Stats
- StreetInsider.com Pre-Open Movers 5/21: (YGE) (SDBT) (ACRX) Higher; (HGG) (CCL) ... 9:34 AM
- Streetinsider.com After-Hours Movers 05/20: (SDBT) (TIVO) (REN) Higher; (HGG) (C... May 20
- NPS Pharma (NPSP) Announces 6M Common Stock Offering Street Insider May 20
- NPS Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of it... May 20
- NPS Pharmaceuticals President and CEO Dr. Francois Nader Recognized as Regional ... May 16
- NPS PHARMACEUTICALS INC Financials May 15
- NPS Pharmaceuticals Recognized by National Organization for Rare Disorders for G... May 15
- NPS Pharma Incurs Narrower 1Q Loss - Analyst Blog Zacks May 14
- NPS Pharmaceuticals Inc Stock Upgraded (NPSP) May 14
- 3 Healthcare Stock Winners and 1 Loser After Earnings Are Digested May 12
NPSP Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). NPS Pharmaceuticals is up 103.8% over the last year vs S&P 500 Total Return up 31.95%, ACADIA Pharmaceuticals up 871.1%, and Vertex Pharmaceuticals up 29.52%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for NPSP
Pro Report PDF for NPSP
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download NPSP Pro Report PDF
Pro Strategies Featuring NPSP
Did NPS Pharmaceuticals make it into our Pro Portfolio Strategies?
NPS Pharmaceuticals, Inc. engages in the discovering, developing and commercializing small molecule drugs and recombinant proteins. Its existing product candidates are primarily for the treatment of bone and mineral, gastrointestinal and central nervous system disorders. The company is currently advancing two late-stage programs. Teduglutide, a proprietary analog of glucagon and preclinical development for additional intestinal failure related conditions. NPSP558 is a clinical development as a hormone therapy for hypoparathyroidism. Its product portfolio consists of a United States Food and Drug Administration approved product, as well as product candidates in various stages of clinical development and preclinical development. NPS Pharmaceuticals, Inc. was founded on October 22, 1986 and is based in Bedminster, New Jersey.